• Pau Llàcer, Mari Ángeles Gallardo, Patricia Palau, Mari Carmen Moreno, Carla Castillo, Cristina Fernández, Rafael de la Espriella, Anna Mollar, Enrique Santas, Gema Miñana, Luis Manzano, Antoni Bayés-Genís, and Julio Núñez.
• Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, España. Electronic address: paullacer@hotmail.com.
• Med Clin (Barc). 2021 Jun 25; 156 (12): 589594589-594.

BackgroundCarbohydrate antigen 125 (CA125) and B-type natriuretic peptides are surrogate markers of congestion in patients with acute heart failure (AHF). The aim of the study was to assess the association between CA125 and NT-proBNP and congestion parameters in patients with AHF.Methods And ResultsProspective multicentre observational study that included 191 patients hospitalised for AHF. We recorded the presence of pleural effusion, peripheral oedema and inferior vena cava (IVC) diameter during the first 24-48 hours after admission and evaluated their independent association with CA125 concentrations and the amino-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP). The mean age was 73.4 ± 12 years, 79 (41.4%) were women, and 127 (66.5%) had left ventricular ejection fraction ≥ 50%. The median of CA125, NT-proBNP and IVC diameter was 58 (22.7-129) U/mL, 3,985 (1,905-9,775) pg/mL and 21 (17-25) mm, respectively. Multivariate analysis showed that CA125 was positively and independently associated with the presence of peripheral oedema, pleural effusion and elevated IVC levels. NT-proBNP was associated with pleural effusion and IVC diameter but not with oedema. The addition of CA125 increased the discriminatory capacity of the baseline model to identify peripheral oedema and pleural effusion, but not NT-proBNP. The most important predictor of ICV dilation was CA125 (R2 = 48.3%).ConclusionIn patients with AHF, serum CA125 levels are associated more significantly than NT-proBNP with a state of congestion.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

23 keywords...

hide…